Top Inhalation Drug Delivery Device Manufacturing Companies in Asia 2026

Inhalation drug delivery device manufacturing companies produce devices that help patients receive medications through controlled respiratory delivery. With a focus on dosage consistency, device usability, quality control and regulatory readiness, they support safer treatment access and more reliable respiratory care.

Solutions

eSonics

Engineering Inhalation Devices Around Drug Performance

Leo Shi (LEI), Founder, Chairman of the Managing Board and CEO

eSonics approaches inhalation-device development from the premise that drug performance and device performance cannot be separated. Small variations in component tolerances can affect dose consistency, aerodynamic particle distribution and clinical outcomes, while regulations add requirements around design control, traceability and GMP-aligned manufacturing. Devices must also serve patients with different dexterity and respiratory conditions.

State of Industry

Advancing Respiratory Care with Inhalation Drug Delivery Device Manufacturing in APAC

In the Asia-Pacific (APAC) region, the manufacturing of inhalation drug delivery devices is a growing segment of the healthcare technology landscape. Inhalation devices deliver medicines directly to the respiratory system, and the design, manufacturing precision, usability and reliability of the device are all critical to the effective delivery of treatment. Manufacturers throughout APAC are developing a range of inhalation technologies, including metered-dose inhalers, dry powder inhalers, nebulizer systems and connected respiratory devices.

Deep Dive

When Inhalation Device Manufacturing Becomes a Drug Development Constraint

Inhalation device programs can lose months when a formulation reaches engineering before the delivery hardware has been tested against it. A small tolerance shift can change dose output or aerosol behavior, while an unsuitable material can create compatibility problems late in development. An inhalation device partner must deliver more than manufacturing precision. It must be able to connect pharmaceutical requirements to repeatable device performance without allowing tooling decisions or design changes to become a new source of development risk. Commercial pressure complicates this further. Early programs need enough prototype fidelity to expose dose and usability risks, but committing too early to production tooling can lock in a device architecture before formulation and clinical requirements have settled. That makes the staging of engineering spend part of the technical evaluation.

Leadership Perspective

Shionogi Inc

Accelerating Early-Stage Drug Development

Safwan Kezbor, M.D., Global Medical Lead (Senior Medical Director), Clinical Development

A great deal of discussion has evolved in the last few years to come up with out-of-the-box creative notions to accelerate the drug development process and shorten the time to deliver innovative, life-saving therapies to patients. There is no doubt that the COVID-19 pandemic has fueled this dialogue in the light of the unprecedented development timelines observed in COVID-19 therapies which challenged both the pharmaceutical industry and the regulatory agencies to apply these accelerated timelines to other therapeutic areas programs. Many great proposals and lessons-learned topics were emphasized, with many already implemented. For most of the fellows engaged in these discussions, the topics were mainly focused on the later stages in drug development which include global multi-centre studies by nature with intensive discussion on boosting enrollment, enhancing study participants' experience and engagement, and delivering numerous effective and convenient options through decentralized clinical trials and other strategies. Understating the fact that late-stage drug development contributes only to a limited part of the entire clinical program strategy will underscore the need for equivalent thoughtful discussion around accelerating the decisionmaking process in earlier phases of drug development.

Inhalation Drug Delivery Device Manufacturing Companies in Asia Info

What Do Top Inhalation Drug Delivery Device Manufacturing Companies in Asia Typically Provide?

Top Inhalation Drug Delivery Device Manufacturing Companies in Asia develop and produce devices that administer medicines through the lungs or nasal passages. Their scope can include device concept and engineering, component development, prototyping, tooling, manufacturing, testing and regulatory documentation. Depending on the therapy, products may include pressurized aerosol devices, dry-powder inhalers, soft-mist systems and nasal delivery devices. The work connects device design with formulation requirements, dose delivery, usability and production controls.

Which Provider Was Recognized for Inhalation Drug Delivery Device Manufacturing in Asia in 2026?

Pharma Tech Outlook recognized eSonics as the Inhalation Drug Delivery Device Manufacturing Company of the Year in Asia 2026. The recognition identifies eSonics within the category represented by Top Inhalation Drug Delivery Device Manufacturing Companies in Asia.

Why Is Demand Growing for Inhalation Drug Delivery Device Manufacturing Companies in Asia?

Demand is being shaped by the wider use of inhaled therapies and the need to deliver medicines through respiratory and nasal routes with greater control. Drug developers also need device partners that can support development from early engineering through manufacturing and regulatory preparation. As therapies become more specialized, device selection can affect dose delivery, patient usability, development timelines and production readiness. These pressures increase the need for specialized inhalation device manufacturers rather than general component suppliers.

What Should Pharmaceutical and Biotechnology Teams Evaluate When Selecting Inhalation Device Manufacturers?

Teams should assess how well Inhalation Drug Delivery Device Manufacturing Companies in Asia can translate formulation and clinical requirements into a manufacturable device. Important considerations include experience with the relevant delivery modality, material and formulation compatibility, dose consistency, human factors, testing methods, quality systems, documentation and process validation. It is also useful to examine how changes are managed during development, how technical data is shared and whether the manufacturer can support the transition from prototype to production without creating avoidable delays or quality risks.

How Do Inhalation Device Manufacturers Apply Technology and Engineering Expertise?

Inhalation Drug Delivery Device Manufacturing Companies in Asia may rely on modality-specific engineering rather than a single design approach. Aerosol devices may require precise valve and sealing control, while dry-powder systems depend on powder flow and dose metering. Soft-mist devices involve fluid dynamics and droplet generation, while nasal delivery devices require control of plume geometry and ergonomics. Simulation, prototyping, bench testing, material screening and human-factor evaluation can help manufacturers verify performance before production.

Why Was eSonics Recognized as Inhalation Drug Delivery Device Manufacturing Company of the Year in Asia 2026?

eSonics was recognized for combining device design, engineering, prototyping, manufacturing and regulatory support across aerosol, dry-powder, soft-mist and nasal platforms. Its development process uses phase-gated engineering, risk assessment, material qualification and design-history documentation. The company also integrates compliance activities into development, including practices consistent with ISO 13485, testing and regulatory documentation. In a nasal-delivery project, it used fluid-dynamic simulation, successive prototypes and dose-uniformity testing to meet a client’s performance requirements.